Find Clinical Drug Pipelines for Cardiology/Vascular Diseases

Lead Product(s): Bempedoic Acid,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2020

Details:

Positive CHMP opinions are based on a global clinical trial programme demonstrating consistent LDL-C lowering across a range of patient populations.

Lead Product(s): CDR132L

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2020

Details:

In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.

Lead Product(s): Bempedoic Acid,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2020

Details:

The CHMP recommended granting the bempedoic acid tablet marketing authorisation for the treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia.

Lead Product(s): D6PV

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Early preclinical studies show peptide D6PV has the ability to activate the enzyme called Lipo-Protein Lipase (LPL), rapidly (within 1 -3 hours) reducing the number of triglycerides in the bloodstream

Lead Product(s): Sirolimus

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $17.3 million Upfront Cash: Undisclosed

Deal Type: Financing January 28, 2020

Details:

Vascular Therapies plans to use the proceeds to further advance Sirogen, a proprietary sirolimus formulation for intraoperative, local, perivascular drug delivery.

Lead Product(s): AKCEA-ANGPTL3-LRx

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3.

Lead Product(s): Propranolol

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Atnahs Pharma

Deal Size: $390 million Upfront Cash: $350 million

Deal Type: Divestment January 27, 2020

Details:

AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.

Lead Product(s): Ticagrelor,Aspirin

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attack.

Lead Product(s): Evolocumab

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Large molecule